ClinicalTrials.Veeva

Menu

Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment

Z

Zeria Pharmaceutical

Status and phase

Completed
Phase 2
Phase 1

Conditions

Pancreatic Cancer

Treatments

Drug: Z-360

Study type

Interventional

Funder types

Industry

Identifiers

NCT00288925
01010106E

Details and patient eligibility

About

To evaluate the safety of two doses of Z-360 with Gemcitabine administration for subjects with unresectable advanced pancreatic cancer in order to determine the optimal dosage for PhaseII study

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subjects with unresectable locally advanced or metastatic pancreatic cancer
  • KPS > 70%
  • Life expectancy of at least 3 months

Exclusion criteria

  • received previous chemotherapy for the current indication
  • received previous radiotherapy for the current indication
  • Currently receiving chemotherapy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems